Clinical TrialJul 7, 2026, 08:21 AM
SAB Biotherapeutics Secures Grant for T1D Clinical Study
AI Summary
SAB Biotherapeutics, Inc. announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., to support the PRISE-hATG clinical study. This study will evaluate SAB-142 in patients with Stage 3 Type 1 Diabetes (T1D) who are 100 days to two years from diagnosis, with SAB BIO co-funding the research. The PRISE-hATG study aims to assess if SAB-142 can preserve endogenous C-peptide and modulate immune responses, expanding the clinical evaluation of SAB-142 beyond earlier stages of the disease.
Key Highlights
- Breakthrough T1D awarded a grant to support the PRISE-hATG clinical study.
- The study evaluates SAB-142 in Stage 3 Type 1 Diabetes (T1D) patients.
- Patients included are 100 days to two years from diagnosis.
- SAB Biotherapeutics will co-fund the PRISE-hATG study.
- The study aims to assess SAB-142's ability to preserve C-peptide and modulate immune responses.
- PRISE-hATG extends SAB BIO's clinical evaluation of SAB-142 and complements the SAFEGUARD trial.
Price Impact
More from SABS